On the stock market since 2025, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 41% a year on average.
Sales run at $116.2M a year. A small number, but proof the product has real buyers.
It pays out $0.04 per share each year — regular cash for whoever holds the stock.
A loss of $747K against $116.2M in annual sales.
On our five-subject report card, STRN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: STRN is a high-risk stock — not yet profitable, and its future rides on its product catching on.